Skip to main content
Christine Kay, MD, Ophthalmology, Gainesville, FL, North Florida/South Georgia Veteran's Health System

ChristineNicholsKayMD

Ophthalmology Gainesville, FL

Retinal Disease

Assistant Professor, Ophthalmology, University of Florida College of Medicine

Are you Dr. Kay?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 54 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Christine Kay, MD is a board certified ophthalmologist in Gainesville, Florida. She is currently licensed to practice medicine in Florida and Iowa. She is affiliated with North Florida/South Georgia Veteran's Health System and is an Assistant Professor at University of Florida College of Medicine.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniResidency, Ophthalmology, 2006 - 2009
  • Carilion Clinic-Virginia Tech Carilion School of Medicine
    Carilion Clinic-Virginia Tech Carilion School of MedicineInternship, Transitional Year, 2005 - 2006
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 2005
  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsResidency, Ophthalmology

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2007 - 2026
  • IA State Medical License
    IA State Medical License 2009 - 2011
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Retinal Gene Therapies in Clinical TrialsMarch 2019

Press Mentions

  • Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
    Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)April 25th, 2023
  • Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1)
    Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1)October 3rd, 2022
  • Will Gene Therapy Comeback Last? Scientists Try to Make It Safer
    Will Gene Therapy Comeback Last? Scientists Try to Make It SaferMay 31st, 2022
  • Join now to see all

Hospital Affiliations